Eli Lilly Blasted Over Cymbalta Labeling In Side Effect Row

Law360, Washington (August 24, 2015, 9:53 PM EDT) -- Eli Lilly and Co. downplayed the withdrawal risk of its antidepressant drug Cymbalta to the point of fraud, a pair of women told a Virginia federal jury Monday, saying the company portrayed their symptoms as rare when almost half of the patients experienced similar withdrawal.

Brent Wisner, attorney for Gilda Hagan-Brown and Janine Ali, said the two women experienced a raft of new symptoms after they stopped taking Cymbalta in 2012 to treat pain associated with their fibromyalgia, such as depression, migraines, pain, fatigue and sensations...
To view the full article, register now.

Related

Sections

Case Information

Case Title

Ali v. Eli Lilly and Company


Case Number

1:14-cv-01615

Court

Virginia Eastern

Nature of Suit

Personal Inj. Prod. Liability

Judge

Anthony J Trenga

Date Filed

November 25, 2014


Case Title

Hagan-Brown v. Eli Lilly and Company


Case Number

1:14-cv-01614

Court

Virginia Eastern

Nature of Suit

Personal Inj. Prod. Liability

Judge

Anthony J Trenga

Date Filed

November 25, 2014

Law Firms

Companies

Government Agencies

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.